Logo image of CADL

CANDEL THERAPEUTICS INC (CADL) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CADL - US1374041093 - Common Stock

6.4 USD
+0.46 (+7.74%)
Last: 1/16/2026, 8:00:02 PM
6.449 USD
+0.05 (+0.77%)
After Hours: 1/16/2026, 8:00:02 PM
Fundamental Rating

2

Taking everything into account, CADL scores 2 out of 10 in our fundamental rating. CADL was compared to 525 industry peers in the Biotechnology industry. While CADL seems to be doing ok healthwise, there are quite some concerns on its profitability. CADL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • CADL had negative earnings in the past year.
  • CADL had a negative operating cash flow in the past year.
  • In the past 5 years CADL always reported negative net income.
  • CADL had a negative operating cash flow in each of the past 5 years.
CADL Yearly Net Income VS EBIT VS OCF VS FCFCADL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

  • CADL has a Return On Assets of -24.32%. This is in the better half of the industry: CADL outperforms 71.81% of its industry peers.
  • CADL has a Return On Equity of -28.40%. This is in the better half of the industry: CADL outperforms 77.33% of its industry peers.
Industry RankSector Rank
ROA -24.32%
ROE -28.4%
ROIC N/A
ROA(3y)-55.97%
ROA(5y)-50.92%
ROE(3y)-140.08%
ROE(5y)-109.18%
ROIC(3y)N/A
ROIC(5y)N/A
CADL Yearly ROA, ROE, ROICCADL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CADL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CADL Yearly Profit, Operating, Gross MarginsCADL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

5

2. Health

2.1 Basic Checks

  • CADL has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for CADL has been increased compared to 5 years ago.
  • Compared to 1 year ago, CADL has an improved debt to assets ratio.
CADL Yearly Shares OutstandingCADL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
CADL Yearly Total Debt VS Total AssetsCADL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • An Altman-Z score of 12.22 indicates that CADL is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 12.22, CADL belongs to the top of the industry, outperforming 84.57% of the companies in the same industry.
  • CADL has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.01, CADL is in line with its industry, outperforming 44.76% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 12.22
ROIC/WACCN/A
WACCN/A
CADL Yearly LT Debt VS Equity VS FCFCADL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

  • CADL has a Current Ratio of 8.25. This indicates that CADL is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 8.25, CADL is in the better half of the industry, outperforming 75.24% of the companies in the same industry.
  • CADL has a Quick Ratio of 8.25. This indicates that CADL is financially healthy and has no problem in meeting its short term obligations.
  • CADL has a better Quick ratio (8.25) than 75.24% of its industry peers.
Industry RankSector Rank
Current Ratio 8.25
Quick Ratio 8.25
CADL Yearly Current Assets VS Current LiabilitesCADL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

  • CADL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 67.42%, which is quite impressive.
EPS 1Y (TTM)67.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, CADL will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.36% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y69.58%
EPS Next 2Y27.86%
EPS Next 3Y18.36%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CADL Yearly Revenue VS EstimatesCADL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2027 2028 2029 2030 2031 2032 2033 500M 1B
CADL Yearly EPS VS EstimatesCADL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CADL. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CADL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CADL Price Earnings VS Forward Price EarningsCADL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CADL Per share dataCADL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CADL's earnings are expected to grow with 18.36% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.86%
EPS Next 3Y18.36%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for CADL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CANDEL THERAPEUTICS INC

NASDAQ:CADL (1/16/2026, 8:00:02 PM)

After market: 6.449 +0.05 (+0.77%)

6.4

+0.46 (+7.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-23
Inst Owners41.76%
Inst Owner Change0%
Ins Owners15.75%
Ins Owner Change0%
Market Cap351.36M
Revenue(TTM)N/A
Net Income(TTM)-22.76M
Analysts82.86
Price Target19 (196.88%)
Short Float %18.53%
Short Ratio10.5
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)18.45%
Min EPS beat(2)-11.2%
Max EPS beat(2)48.1%
EPS beat(4)2
Avg EPS beat(4)26.75%
Min EPS beat(4)-72.38%
Max EPS beat(4)142.48%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-5.3%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-7.75%
EPS NY rev (1m)0%
EPS NY rev (3m)-17.92%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.39
P/tB 4.39
EV/EBITDA N/A
EPS(TTM)-0.57
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)-0.61
FCFYN/A
OCF(TTM)-0.61
OCFYN/A
SpS0
BVpS1.46
TBVpS1.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -24.32%
ROE -28.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.97%
ROA(5y)-50.92%
ROE(3y)-140.08%
ROE(5y)-109.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.53%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.25
Quick Ratio 8.25
Altman-Z 12.22
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)71.98%
Cap/Depr(5y)525.77%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)67.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.79%
EPS Next Y69.58%
EPS Next 2Y27.86%
EPS Next 3Y18.36%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-15.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-31.49%
EBIT Next 3Y-5.1%
EBIT Next 5Y83.51%
FCF growth 1Y1.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.45%
OCF growth 3YN/A
OCF growth 5YN/A

CANDEL THERAPEUTICS INC / CADL FAQ

Can you provide the ChartMill fundamental rating for CANDEL THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to CADL.


Can you provide the valuation status for CANDEL THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to CANDEL THERAPEUTICS INC (CADL). This can be considered as Overvalued.


What is the profitability of CADL stock?

CANDEL THERAPEUTICS INC (CADL) has a profitability rating of 1 / 10.